CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype by unknown
CD40 and B  Cell Antigen Receptor Dual Triggering 
of Resting B  Lymphocytes Turns on a 
Partial Germinal Center Phenotype 
By Laurent Galibert,  Nicolas Burdin,  Blandine de Saint-Vis, 
Pierre Garrone, Cees Van Kooten,Jacques Banchereau, 
and Fran~oise Rousset 
Ftvm Schering-Plough,  Laboratory for Immunological Research,  69571  Dardilly,  France 
Summary 
Phenotypic  alterations  occur  when  resting  human  B  lymphocytes become  germinal  center 
(GC) cells.  These include the induction of surface CD38, CD95 (FAS/APO-1), and carboxy- 
peptidase-M  (CPM), a recently described GC marker. However, the factors that govern the in 
vivo induction of these surface molecules on B cells remain unknown. Here, we purified rest- 
ing (CD38-)  human B  lymphocytes from tonsils in an attempt to establish  culture conditions 
resulting  in  the  induction  of these  three  GC  markers.  We  show  that  interferon  (IFN)  0t  or 
IFN-% as well as antibodies against the B cell antigen receptor (BCR), could induce CD38 on 
resting B lymphocytes, a phenomenon further enhanced by CD40 stimulation.  Concomitantly, 
CD95 was upregulated by CD40 ligation and, to a lesser extent, by IFN-% By contrast, CPM 
expression could be upregulated only through BCR triggering. This CPM induction was spe- 
cifically enhanced by CD19  or CD40  ligation.  CD40  +  BCR  stimulation  of resting B  cells 
with CD40 ligand-transfected fibroblastic cells in the presence of cross-linked anti-BCIL mono- 
clonal antibodies  resulted in the coexpression of CD38,  CD95, and CPM.  As GC cells,  these 
cells  also expressed CD71, CD80 (B7.1), and CD86 (B7.2), but not CD24.  However, CD10 + 
or CD44- B  cells could not be detected in these culture conditions, suggesting that yet other 
signals are required for the induction of these GC markers.  Consistent with a GC phenotype, 
CD40  +  BCR~timulated  cells  exhibited reduced viability when cultured for 20 h  in the ab- 
sence  of stimulus.  These  results  first demonstrate  that  cotriggering of resting B  ceUs through 
BCR  and  CD40  induces both phenotypic  and  functional  GC  features.  They also show that 
IFN and CD19 triggering of resting B cells specifically modulate the expression of GC markers. 
A 
fter antigenic challenge, a large variety of cells sequen- 
tially  cooperate  to  develop  the  humoral  response. 
APC take up the antigen,  process it,  and present it to spe- 
cific  Th  cells  in  the  context  of MHC  class  II molecules. 
This  cognate  interaction  drives  Th  cells  to  express  both 
membrane-associated  and  soluble  factors  that  control  the 
proliferation and differentiation  of B  lymphocytes.  In sec- 
ondary  lymphoid  organs,  this  Th-B  cell  interaction  is  a 
prerequisite  for  the  fomlation  of germinal  centers  (GC), l 
the histological structures where B lymphocytes proliferate 
and mature into high-affinity memory cells  (for reviews see 
references  1, 2). 
In humans,  several phenotypic alterations occur when B 
lymphocytes enter GC. These include both induction and 
disappearance  of various  surface  molecules  (CD  markers) 
that most likely reflect B cell activation and adaptation to a 
t Abbreviations used in this paper: BCIL, B cell antigen receptor; CPM, car- 
box~'peptidase M; GC, gentfinal centers. 
new environment. Among GC markers,  CD38 is a surface 
enzyme  catalyzing  the  synthesis  of  cADP-ribose  from 
NAD (3-7).  CD38 is believed to participate  in the control 
of GC B  cell growth (4)  or viability (8)  and is coexpressed 
on GC cells with the carboxypeptidase  M  (CPM),  a zinc- 
dependent protease known to cleave offbasic COOH-ter- 
minal amino acids from hormonal peptides  (9).  In addition 
to these two ectoenzymes, GC cells express on their surface 
CD95  (FAS),  a  TNF  receptor-related  molecule  that  also 
participates in the control of GC B cell survival (10,  11). 
Here,  we  attempted  to  establish  culture  conditions  re- 
sulting in the induction of a GC phenotype on resting ton- 
sillar  B  cells.  This  approach  allowed  us to  show that  dual 
triggering  of CI)40 and B  cell antigen  receptor  (BC1L) is 
required  for the coexpression of CD9S, CD38, and CPM. 
It  also  showed  that  cells  coexpressing  these  markers  are 
highly susceptible  to  spontaneous  cell  death.  Finally,  it  is 
suggested that  IFNs as well as CD19 triggering contribute 
to the in vivo acquisition of a GC phenotype. 
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Cytokines.  rhlL-lot and rhlL-1[3 (108 U/mg), rhlL-6 (107 U/ 
rag), and rhTNF-c~ (2  ￿  107 U/rag) were purchased from Gen- 
zyme Corp.  (Boston, MA). They were used at 10,  10, 200, and 
2.5 ng/ml, respectively. Purified rhlL-2 (3 X  106 U/ml) (Amgen 
Biologicals, Thousand Oaks, CA), rhlL-3 (5 X  106 U/mg), rhlL-4 
(107 U/mg), rhlL-5 (107 U/mg), rhlL-10 (107 U/ml), rhlL-13 (106 
U/ml), and rhGM-CSF (2  ￿  106 U/rag)  (Schering-Plough tke- 
search Institute. Kenilworth, NJ)  were used at 20 U/ml,  10 ng/ 
ml, 50 U/nfl,  100 ng/ml,  100 ng/nfl, 50 ng/nd, and 100 ng/nd, 
respectively, rhlFN-~x (107 U/mg) (provided by Schering-Plough 
Research Institute) was used at 2,000 U/ml. rlL-12 (2-3  ￿  103 
U/ml) was kindly provided by Dr. A. O'Garra (DNAX Research 
Institute, Palo Alto, CA) and was used at 10 ng/nd. TGF-[31 and 
rhlL-7  were  obtained from  R&D  Systems,  Inc.  (Minneapolis, 
MN)  and were used at 0.5 and  100  ng/ml, respectively. IFN-y 
(107 U/rag) was purchased front Amgen Biologicals and was used 
at 500 U/ml. 
Antibodies.  The  monoclonal and polyclonal antibodies used 
for phenotypic and functional studies were obtained from the fol- 
lowing sources: anti-CD2 and anti-CD3 nkAbs used for negative 
selection of B  cells with magnetic beads (Aster Laboratories, La 
Gaude, France);  PE-conjugated anti-CI)2 (Leu 5), anti-CD3 (Leu 
4), FITC-conjugated anti-CD10 (Calla), anti-CD20 (Leu  16), and 
anti-CD14 (Leu M3) antibody (Becton Dickinson & Co., Moun- 
cain View, CA); FITC-conjugated anti-Bcl-2 oncoprotein (Dako- 
patts A/S, Glostrup, Delmaark); anti-K (6E1), anti-~. (C4) anti-CD24 
(IOB3),  FITC-conjugated anti-CD19  (IOB4),  and biotin-con- 
jugated anti-CD24  (1OB3)  antibodies (lnununotech,  Marseille, 
France); FITC-conjugated anti-CD44  (A3DS) antibody and bi- 
otinylated goat anti-human lgD antibody (Sigma Chemical Co., 
St.  Louis, MO);  PE-conjugated anti-CD86  (B70)  (PharMingen, 
San Diego, CA). 
The  anti-CD40  (mAb  89)  (12),  anti-CPM  (M27)  (9),  anti- 
CD21  (FIP6, FIP8, and FIP15), and anti-CD40-L (LL2) mAbs 
were  generated  and  purified  in  our  laboratory.  Anti-CD38 
(OKT10) antibody was purchased from Anterican Type Culture 
collection (tLockville, MD) (CRL-8022) and used as ascitic fluid. 
Anti-CD19  (4G7)  and  PE-conjugated anti-CDS0  (L307)  were 
kindly provided by Drs. R.  Lew and L. Lanier, respectively. M1 
other antibodies were obtained from the V  ~h International Work- 
shop on Leucocyte Typing (Boston, MA, 1993). 
Chemicals.  FITC-conjugated streptavidin was purchased from 
hnmunotech. 
Flow Cytometfic Analysis.  Antibody binding was  analyzed on 
a FACScan  *  flow cytometer (Becton Dickinson & Co.). Gating 
was  set according to  forward angle light scatter parameters and 
propidium iodide staining to  exclude subcellular particles, dead 
cells, and L cells from acquisition data.  Data (l& events per sam- 
ple)  were  subsequently  processed  using  the  LYSYS  program 
(Becton Dickinson & Co.). The percentage of positive cells was 
deternfined by channel per channel peak substraction of the con- 
trol histogram using the Consort 30 program (Becton Dickinson 
& Co., lmnmnocytometry Systems).  For intracellular detection of 
Bcl-2 protein, cells were permeabilized by 15-rain incubation at 
4~  in  saponine  (0.5  mg/ml)  before  staining  with  anti-Bcl-2 
mAb or an unrelated mAb as a negative control. Cell viability was 
determined by measurement of the incorporation of the DNA- 
binding fluorochromes  Bisbenzimide  HOECHST  33342  (Cal- 
biochem-Novabiochem Corp..  San  Diego,  CA) and propidium 
iodide, as previously described (13).  Cells were incubated for 5 
min with 10 ~,M HOECHST 33342  and 32 ~M propidium io- 
dide immediately before analysis  with  a  double  laser-equipped 
FACStar  |  plus (Becton Dickinson & Co.). This analysis permit- 
ted us to delineate three different cell populations: (a) Pemaeable 
cell membranes incorporate propidium iodide; (b) apoptotic cells 
incorporate only HOECHST  33342;  (c) viable cells incorporate 
neither propidium iodide nor HOECHST 33342. 
B Cell Cultures.  All cultures were perforated in RPMI  1640 
medium enriched with 2 mM t-glutamine (Gibco Laboratories, 
Grand Island,  NY),  10%  heat-inactivated FCS (Flow Laborato- 
ries,  &vine, Scotland), 80 Ixg/ml gentamicin (Gencalline; Scher- 
ing-Plough),  in  the  presence  of irradiated  (7,00()-rad)  CD32- 
transfected (CD32-L  cells;  American Type  Culture  Collection, 
16.2  CG7)  or CD40-L/CD32-double  transfected routine  Ltk- 
cells.  The CD40-L/CD32-double  transfected L cells were pro- 
duced in our laboratory. Cultures were set up  in flat-bottomed 
96-well microtiter plates (100 txl final volume) in the presence of 
5  ￿  103  transfected L  cells/well and  104-105 purified B  cells. 
Anti-CD or anti-BCR were used at 2 Ixg/ml or 1  : 1,000 dilution 
ofascitic fluid throughout this study. 
B Cell Purification.  Tonsillar  mononuclear  cells  were  sepa- 
rated by standard Ficoll-Hypaque gradient method and were next 
submitted to E  rosetting with SfLBC.  The following procedure 
was designed according to Lagresle et al. (14).  Nonrosetting cells 
were labeled with anti-T cell (anti-CD2, -CD3, -CD4, and -CD8 
mAbs), anti-monocyte (anti-CD14 mAb), and anti-CD38 (OKT10) 
mAbs  and  subsequently  incubated  twice  with  magnetic  beads 
coated with anti-mouse lgG antibodies (Dynal, Oslo, Norway). 
Labeled cells were removed by applying a magnetic field for  15 
min.  The  purity of the B  cell subpopulation obtained after this 
procedure was >98% as estimated by FACScan  |  inmmnofluores- 
cence labelings performed with CD2, CD3, CD4, CDI9, CD38, 
and CD44  mAbs. For triple-labeling experiments, cells were la- 
beled by biotinylated goat-anti-IgD antibody +  tricolor-strepta- 
vidin and indirect mAb +  PE-conjugated anti-mouse antibody. 
After saturation with mouse serum, FITC-conjugated anti-CD38 
was added. 
Results 
CD38-  Tonsillar B  Cells Indude Both Naive and Memory B 
Cells.  The  phenoWpe  of highly purified tons/liar B  cells 
was  assessed  using  triple  labeling  with  (a)  anti-CD38 
(FITC),  (b)  anti-IgD  (Tricolor),  and  (c)  PE-conjugated 
anti-CD20,  anti-CD95  (FAS),  anti-CPM,  anti-CD71, 
anti-CD80  (B7.1),  anti-CD86  (B7.2),  anti-CD24,  anti- 
CD10, or anti-CD44 mAbs. Results are shown in Fig. 1 ,'1. 
From these labelings, two  different tonsillar B  cell subsets 
can be distinguished: (a) CD38 l~  cells, which are resting 
and  include  both  slgD +  naive  and  slgD-  memory  cells 
(gate  R1)  (14-16);  and  (b)  CD38 h~gh cells,  which  corre- 
spond to GC B  lymphocytes. Consequently, in this report, 
resting tonsillar B  cells were  selected by  CD38  depletion 
(14).  As expected, the resulting population (Fig.  1 B)  wpi- 
cally included variable proportions of slgD-" cells. CD38-- 
purified B  cells also expressed low levels of CD95,  CD80, 
CD86,  and CD71,  and no CPM,  but high levels of CD24 
and CD44 antigens. 
IFN-o6 IFN-T, or BCR Ligation Induce CD38 Expression on 
Resting Tonsillar B  Cells.  We first examined the in vitro in- 
duction  of surface  CD38  expression  on  resting  (CD38-) 
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Figure  1.  (A) Triple labeling of human tonsillar B cells. B lymphocytes were purified from tonsils and labeled as reported in Materials and Methods. 
Gate R1, resting cells; R2,  GC cells.  (B) Phenotype of CD38- tonsillar B lymphocytes. B  cells were purified from tonsils and then labeled with anti- 
CD38 mAb. After adding anti-mouse Ig-coated beads, CD38  + cells were depleted on a magnet. Remaining cells were phenotyped. Each staining profile 
(solid line) was superimposed onto that of the negative control (dotted line) performed with an isotype-matched unrelated mAb. 
tonsillar B  cells.  To  this  end,  resting B  lymphocytes were 
cultured  with  optimal concentrations  of cytokines  (IL-l(x, 
IL-113, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, 
IFN-oL, IFN-%  GM-CSF,  or TNF-o0,  anti-BC1K or anti- 
CD40  mAbs in  the  presence  of CD32-L  cells.  CD38  ex- 
pression was then determined  at day 3  by FACS |  analysis. 
Among the cytokines tested,  only IFN-o~ and IFN-~ were 
found to consistently induce CD38  expression on resting B 
lymphocytes  (Fig.  2 A). This IFN-mediated  CD38  induc- 
tion was observed at as early as 18 h  of culture and reached 
near maximal levels after 24  h  (Fig.  2  A).  The IFN-c~ and 
IFN-',/-mediated induction of CD38 was a dose-dependent 
process with a half-maximal effect observed at "-~5 and ,'-~1 U 
and an optimal effect at N1,200  and "~300 U, respectively 
(Fig. 2  B).  This induction  was a direct effect of IFNs on B 
cells because it could be seen in the absence of fibroblastic 
CD32-L cells  (not shown).  Triggering of BC1K by immo- 
bilized  anti-K+K  light  chain  mAbs was  also  found  to  in- 
duce  a  moderate  expression  of CD38.  This  anti-BC1K- 
induced  CD38  expression  displayed  slower  kinetics  than 
that observed with IFN-(x and IFN-~/with  an optimal ex- 
pression around day 5  (Fig.  2 A). At this time point,  22  -Z_ 
9% (n  =  3)  of cells expressed CD38.  In contrast,  although 
it is the most efficient mitogenic signal, CD40 triggering by 
immobilized anti-CD40  mAb (mAb 89) essentially failed to 
turn on CD38  expression (Fig. 2 A). 
IFN-  or BCR-induced  Expression  of CD38  Is  Further  En- 
hanced by CD40 Ligation.  Because CD40 stimulation  sen- 
sitizes B cells to anti-BCR triggering (17) and to a large variety 
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of cytokine  effects,  we  tested  whether  CD40  stimulation 
would  affect  anti-BC1K-  or  IFN-mediated  induction  of 
CD38.  To this end, resting (CD38-)  tonsillar B  cells were 
stimulated with either anti-BC1K (anti-K+k light chains) or 
anti-CD40  (1-nAb 89)  antibodies  cross-linked  on  CD32-L 
cells, with or without  optimal concentrations  of IFN-oL or 
IFN-% After 3  d  of culture,  CD38  expression on activated 
B  cells  was  determined  by  FACS |  analysis.  Results  are 
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Figure  2.  IFNs or BCK stimulation induce CD38 expression on the 
surface of resting tonsillar B cells. CD38- resting B lymphocytes were pu- 
rified from tonsils as reported in Materials and Methods and seeded with 
CD32 § fibroblasts in the presence of (A) medium (A), IFN-a (2,000 U) 
(O), IFN-~/(500 U) (O), mAb89 (2 lag/ml) (IN), or anti-K +  anti-k light 
chain mAbs (2 I.Lg/ml each) (B), or in the presence of (B) variable con- 
centrations of IFN-(x (O) or IFN-~/ (O). CD38 expression was measured 
by FAGS  |  The percentage of positive cells was determined by subtrac- 
tion of the control peak. Results are representative of three independent 
experiments. Medium 
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Figure 3.  Double-entry table of in vitro-activated resting B ceil CD38 
profiles. CD38- B lymphocytes were cultured in the presence ofCD32 + 
fibroblasts with  or without  IFN-ot, IFN-% anti-BCR,  anti-CD40,  or 
combinations. On day 3, cells were labeled with FITC-conjugated anti- 
CD38 mAb. Staining profile of CD38 (solid line) was superimposed onto 
that of FITC-conjugated  isotype-matched unrelated mAb  (dashed line). 
Shaded squares indicate combinations with synergistic  or additive effects. 
These results are representative of four experiments. 
shown as a double entry table with CD38 labeling FACS  | 
profdes  obtained  for  each  combination  (Fig.  3).  CD40 
stimulation  significantly enhanced  BCR-induced  expres- 
sion of CD38.  Similarly, IFN-c~- or IFN-y-driven expres- 
sion of CD38 could be further enhanced by CD40 stimula- 
tion. Moreover, combined stimulation oflFNs and anti-BCR 
or IFN-o~ and IFN-y displayed synergistic effects on CD38 
expression.  Thus,  CD40  stimulation of resting tonsillar B 
lymphocytes  could  enhance  anti-BCR-  or  IFN-induced 
expression of CD38. 
CD40  Triggering or IFN- T  Upregulate CD95  (FAS) on the 
Suface of Resting B Lymphocytes.  GC B cells coexpress CD38 
and CD95 antigens; thus, we examined whether CD95  ex- 
pression would be upregulated in vitro on CD38-  B  cells. 
Consistent  with  previous  studies  (10,  11,  18),  only  anti- 
CD40 and IFN-y significantly enhanced surface CD95  ex- 
pression  on  CD38-  B  cells  after  a  3-d  culture  period, 
whereas  IFN-~x remained virtually inactive  (Fig.  4).  IFN- 
y-induced  CD95  expression  displayed  donor  variability 
(A%(IFN_v) =  53  +  44%,  n  =  4).  In  contrast,  anti-CD40 
consistently induced CD95  on the surface of resting B  cells 
(A%(mab89)  =  88  •  7%,  n  =  4).  Addition  of IFN-y  to 
CD40-activated resting B  cells did not result in significant 
upregulation of CD95  expression. Interestingly, anti-BCR 
triggering partially counteracted both  IFN-y-  and CD40- 
induced  expression  of CD95.  Therefore,  coexpression  of 
CD38  and  CD95  (Figs.  3  and  4)  can  be  achieved  using 
IFN-y and, more reproducibly, with anti-CD40 mAb plus 
IFN-o~, IFN-y, or anti-BCR. 
CPM  Expression  Is  Induced  by  BCR  Triggering and  En- 
hanced by CD19 or CD40 Ligation.  We  recently  reported 
Figure 4.  Double-entry table of in vitro-activated resting B cell CD95 
profiles. CD38- B lymphocytes were cultured in the presence ofCD32 + 
fibroblasts  with or without IFN-~x,  IFN--/, anti-lg, anti-CD40, or combi- 
nations. On day 3, cells were labeled with FITC-conjugated anti-Cl)95 
mAb. Staining profile of CD95 (solid line) was superimposed onto that of 
FlTC-conjugated isotype-matched unrelated mAb (dotted line). 
the presence of CPM  on the surface of CD38 + leukocytes 
(9).  Among  mature  B  lymphocytes,  only  GC  cells  ex- 
pressed  this  ectoenzyme  (Fig.  1).  Moreover,  as  well  as 
CD38 and CD95,  in vivo expression of CPM appears to be 
an early event of B  cell activation inasmuch as this enzyme 
is  expressed  on  early  (slgD  +)  unmutated  GC  cells  (Le- 
becque,  S.,  O.  de Bouteille, C.  Arpin, J.  Banchereau,  and 
Y.-J.  Liu,  manuscript  in  preparation).  In  vitro,  neither 
CD40 stimulation nor 16 tested cytokines (see above), used 
alone or in combination, could induce CPM expression on 
CD38-  B  cells (Fig. 5). BCR  triggering was thus the only 
efficient stimulus  able  to  induce  surface  CPM  expression 
on  CD38-  tonsillar B  cells. Indeed,  as shown  in  Fig.  5,  a 
fraction  (13  +  4%,  n  =  4)  ofCD38-  B  lymphocytes cul- 
tured  in  the  presence  of cross-linked anti-BCR  were  in- 
duced to  express CPM.  This induction  could be observed 
as soon as day 3  and increased up until day 6  (not shown). 
Anti-BCR--induced  expression  of CPM  was  significantly 
enhanced  by  anti-CD40  mAb  and  to  a  lesser  extent  by 
IFN-or  (Fig.  5).  In  contrast,  IFN-y partially counteracted 
the  induction  of CPM.  When  analyzing other  costimula- 
tory antibodies,  it was  found  that  anti-CD19  mAbs were 
also  capable of enhancing  the  anti-BCR-induced  expres- 
sion of CPM. As shown in Fig. 6, A  and B, the anti-CD 19 
mAbs  and  the  anti-CD40  mAbs  strongly  enhanced  anti- 
BCR-induced  expression  of CPM,  thus  confirming  the 
specific role of these molecules. Anti-CD21  mAbs stimu- 
lated  slightly  but  reproducibly  anti-BCR-induced  CPM 
expression (Fig. 6, A  and B). In contrast, antibodies specific 
for CD20,  CD22,  HLA-DR,  and CD81  failed to enhance 
the  expression  of CPM  on  anti-BCR-activated  B  cells. 
The  enhancing  effect of CD40  ligand or anti-CD19  trig- 
gering was also observed for low anti-BCR concentrations 
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profiles. CD38- B lymphocytes were cultured in the presence ofCD32 + 
fibroblasts  with or without IFN-ct, IFN-"/, anti-Ig, anti-CD40, or combi- 
nations. On day 3, cells were labeled with biotin-conjugated anti-CPM 
mAb. Staining profile of CPM (solid line) was superimposed onto that of 
biotin-conjugated isotype-matched  unrelated  mAb (dashed line). Shaded 
squares indicate combinations with synergistic or additive effects. 
(Fig. 6  C). However, the minimal anti-BCR concentration 
needed  for  day  4  CPM  induction  was  not  significantly 
lowered by CD40  ligand or anti-CD19  mAbs  (Fig.  6  C). 
Finally, because  in  vivo  CPM  expression  is  restricted  to 
CD38 +  leukocytes  (9),  CD40  +  BCR-  or  CD19  + 
BCR-stimulated  resting  B  cells  were  labeled  with  anti- 
CD38  and  anti-CPM  mAbs.  As  illustrated  in  Fig.  6  D, 
CPM +  in vitro-activated B  cells also  expressed  the  CD38 
molecule  (Fig.  6  /7)). Noteably,  the  addition  of cytokines 
(IL-2, IL-3, IL-4,  IL-10, or IFN-00 to  CD19  +  BCR-  or 
CD40  +  BCR-activated B  cells only displayed a  marginal 
effect  on  CPM  expression  (not  shown).  Thus,  CPM  is  a 
GC  marker  that  can be  induced by mitogenic concentra- 
tions ofanti-BCR  and specifically requires CD19 or CD40 
triggering for optimal expression. 
Cotriggering of Resting B  Cells  through BCR  and CD40 In- 
duces Both Phenotypic and Functional GC Features.  Triggering 
of resting  B  cells  with  combinations  of different  stimuli 
(CD40  ligand +  anti-BCR,  anti-CD19  +  anti-BCR)  re- 
sulted in potent induction of CPM  and CD38.  Thus,  we 
tested whether  these  combinations could upregulate  other 
GC markers. As shown in Fig. 7, CD40  +  BCR  triggering 
induces loss  of CD24  antigen and coexpression  of CD38, 
CD71,  CD95,  CD80,  CD86,  and CPM  on resting tonsillar 
B  cells.  As  a  control,  cells  stimulated  with  CD40  ligand 
alone do not express  CD38  or CPM.  In contrast to  CD40 
+  BCR-activated  lymphocytes,  CD19  +  BCR-activated 
resting  B  cells  remained  CD711~  and  CD95-.  None  of 
these  culture conditions, however,  could generate CD10 + 
or  CD44-  B  lymphocytes  from  resting  tonsillar  B  cells, 
suggesting  that  yet  other  signals  are  required  to  induce  a 
full GC phenotype.  Adding IFN-ci, IFN-%  or anti-CD19 
to CD40  +  BCR-stimulated resting B  cells did not signifi- 
cantly  change  the  pattern  of expression  of these  markers 
(not shown).  Similarly, we  could not downregnlate CD44 
expression  or induce CD10  by adding GM-CSF  (19),  su- 
pematant  of  an  anti-CD3-activated  T  cell  clone,  anti- 
CD44 mAbs, or collagen type I, a natural ligand for CD44 
(20)  (not shown). 
As GC B  cells undergo spontaneous apoptotic cell death 
when cultured in medium (21), we asked whether the ob- 
served in vitro acquisition of a  GC phenotype is associated 
with  reduced  viability.  Resting  B  lymphocytes  were  iso- 
lated  from  tonsils and  cultured for  6  d  in the  presence  of 
CD40  ligand/CD32 +  L  cells  with  or  without  anti-BCR 
antibodies.  B  cells were  then harvested,  washed,  and fur- 
Figure 6.  CPM expression on in 
vitro-activated  CD38-  B  cells. (A) 
CD38-  tonsillar B  cells were  cul- 
tured in the presence of CD32  + fi- 
broblasts with 2 Ixg/nfl of anti-K and 
anti-k mAbs with or without anti- 
CD19  (4G7), anti-CD20  (MEM- 
97), anti-CD21  (FIP8),  anti-CD22 
(3H4),  anti-CD40  (mAb89),  anti- 
CD81  (1D6),  or  anti  HLA-DP,. 
(449B4) mAbs. Cells were  then la- 
beled  with  biotin-conjugated anti- 
CPM  +  streptavidin-FITC.  (/3) 
Anti-K+k-activated cells were  cul- 
tured  with  or  without  anti-CD19, 
CD20,  CD21,  CD22,  CD40,  or 
HLA-DR  mAbs  and  labeled  as 
above. The source of mAbs and the 
method for the determination of the 
percentage  of positive cells are  de- 
scribed in Materials and Methods. Results are representative of three independent experiments. (C) Percentage of CPM  + cells after stimulation with sub- 
optimal concentrations ofantiqg. CD38- B cells were cultured for 4 d on CD40 ligand/CD32 double-transfected Ltk  cells  in the presence of variable 
concentrations ofanti-Ig (K+k) (O, [Z, O), 2 Ixg/ml anti-CD40-L (LL2) ([~, Q) or 2 btg/ml anti-CD19 ([]) antibodies before labeling with M27 mAb. 
(D) CD38- tonsillar B cells were cultured for 4 d in the presence of anti-CD19 +  anti-Ig. Cells were then harvested and labeled with FITC-conjugated 
anti-CD38 mAb and streptavidin-PE +  biotinylated anti-CPM mAb. 
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Figure 7.  CD40-L +  anti-Ig cotriggering 
induces  phenotypic  features of  GC  cells. 
CD38  B  cells were cultured for  6  d  on 
CD40-L/CD32-transfected  fibroblasts with 
or without anti-K+k or on CD32-transfected 
fibroblasts in the presence of anti-K+k and 
anti-CD19 mAbs. Living cells were labeled 
with  FITC  or  PE-conjugated  antibodies. 
Staining profile (solid line) was superimposed 
onto  that of a  conjugated isotype-matched 
unrelated mAb (dotted line). 
ther cultured in medium for an additional 20 h in the pres- 
ence of anti-CD40 ligand antibody to avoid triggering by 
contaminating  L cells. As shown in Fig. 8 A, when harvested, 
both CD40- and CD40  +  BCR.-stimulated resting B  cells 
A  CD~O 
Bcl2 expression 
B  O--O c~0 
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~ 
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Figure 8.  Cells  with GC phenotype are highly susceptible  to spontane- 
ous cell death. Resting tonsillar  B lymphocytes  were cultured for 6 d in 
the presence of CD40-L/CD32-transfected  L cells with or without 2 Ixg/ 
ml ofanti-K + anti-k antibodies. Cells were then harvested, washed and 
(A) labeled  with Bcl-2 mAb after saponine  treatment. Dashed line, CD40 
activated cells; solid  line: CD40 + Ig-activated cells; dotted line, isotype- 
matched control. Cells  were further cultured in medium. (B) Time course 
measurement of viability  using trypan blue. (C) After 20 h in secondary 
culture, cells were stained with propidium iodide +  HOECHST 33342 
as described in Materials and Methods. (Left) CD40-activated  cells. (Right) 
CD40 + lg-activated cells. The upper quadrant correspond to dead cells, 
the lower left to viable cells, the lower right to apoptotic cells. Numbers 
indicate the percentage of events recorded for each of these three subsets. 
express high and comparable amounts of  Bcl-2 protein. How- 
ever, unlike CD40-activated lymphocytes, CD40  +  BCR.- 
triggered  cells  undergo  rapid  cell  death  as  measured  by 
trypan  blue  exclusion  (Fig.  8  B).  This  spontaneous  cell 
death  can  also  be  quantified  by  propidium  iodide  and 
HOECHST  33342  double  labeling  (13).  Using  this 
method,  after  20  h  in  medium,  only  14%  of CD40  + 
BCR-triggered cells appear viable (Fig. 8  C, right),  whereas 
68% of cells that received only the CD40 triggering are vi- 
able (Fig. 8  C,  left). This rapid loss  of viability may be due 
to apoptotic cell death because a sizeable (14%)  proportion 
of CD40  +  BCP,-activated cells exhibits condensed chro- 
matin and an integral plasma membrane structure. 
Discussion 
Early histophysiological studies have shown that the GC 
is a T  cell-dependent structure. Indeed, individuals with a 
complete T  cell defect do not form GC (22). The interac- 
tion between CD40 on B  cells with its ligand on Th cells 
recently emerged as  an essential component of this Th-B 
cell  crosstalk  because  a  defective  expression  of CD40  or 
CD40 ligand leads to a GC formation defect (23-26). The 
implication of CD40-CD40 ligand interaction in the  GC 
reaction is further illustrated by the  fact that both isotype 
switching and  the  somatic  mutation processes--two  mo- 
lecular events that take place in GC--are absent in patients 
displaying the nonfunctional CD40 ligand gene (27-30, D. 
P,  azanajaona, C.  Van Kooten, S.  Lebeque, J.  M.  Bridon, 
S.  Ho,  S.  Smith, R.  Callard, J. Banchereau, and F. BriSre, 
manuscript  in  preparation).  As  shown  in  this  report,  in 
vitro CD40  stimulation of B  cells leads to  several pheno- 
typic alterations that occur in the GC.  Thus, in agreement 
with former reports (10,  11, 31, 32), CD40 stimulation in- 
duces  the  coexpression  of  CD95  (FAS),  CDS0  (B7.1), 
CD86  (B7.2),  and  CD71  surface  molecules.  In addition, 
CD40 triggering leads to the disappearance of CD24  anti- 
gen which, in vivo, marks B  cell entry into the  GC  (33). 
When combined with certain cytokines such as IFN-~ or 
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expression.  This result  is consistent  with  a  previous report 
showing  that  immunoreactive  IFN-ix  can  be  detected  in 
GC  tingible  body macrophages  of human  secondary  lym- 
phoid  tissues  (34).  A  high  frequency  of spontaneous  IFN- 
"y-producing T  cells is also  present  in  human  tonsils  (35). 
These  IFN-'g-producing T  cells are mainly located  in the 
extrafollicular area (36), where  CD40-L+-activated  T  ceils 
are  also  detected  (37-39).  Accordingly,  in  vivo  CD40  + 
IFNs stimulation  of antigen-specific  B  lymphocytes  could 
indeed take place in human lymphoid tissues and drive the 
induction  of CD38. 
Although it has been clearly demonstrated that antigen is 
essential  for  the  GC  reaction,  little  is  known  concerning 
the  site  and  context  of the  B  cell-antigen  encounter.  In 
vitro experiments have shown that antigenic stimulation of 
B  cells is critical for effective Th-B  cell collaboration  (40). 
Indeed,  BCR  triggering by multivalent  antigen  appears to 
be necessary for the  induction  of CD28  ligands  (CD80  or 
CD86)  on the B  cell surface (41).  These CD28  ligands are 
required for full Th cell proliferation and cytokine produc- 
tion, which, in turn, would control B cell blastogenesis.  In- 
terestingly,  efficient triggering  of BCR  is also necessary to 
sensitize  B  cells  to  Th  cells  expressing  low  (physiological) 
levels  of CD40  ligand  (42).  In  vivo,  this  efficient  BCR 
stimulation  could be achieved in the presence of accessory 
cells like follicular dendritic  cells (43)  retaining  the  unpro- 
cessed antigen  on  their surface.  Here  we  show  that BCR 
stimulation can contribute  to the acquisition of CD38 anti- 
gen. In addition, BCR triggering is the only signal tested so 
far that allows the  induction  of CPM,  a surface membrane 
enzyme  specifically  expressed  on  GC  mature  B  cells  (9). 
Anti-BCR  induction  of CPM  is further enhanced by anti- 
CD40  or,  to  a  lesser  extent,  by  anti-CD19  cotriggering. 
The  contribution  of CD19  or CD40  molecules  to the  in- 
duction  of CPM  was specific in  that antibodies  against six 
other  surface  molecules  failed  to  display  such  an  activity 
(see  Fig.  6,  A  and  B).  Recent  experiments  in  mice  have 
shown  that CD19  is necessary for the formation of GC in 
response  to  T  cell-dependent  antigens  (44).  CD19  is a  B 
cell-restricted  type I protein with  a large extracytoplasmic 
portion comprising two Ig-like domains. The CD19  extra- 
cellular portion  also  includes  a  potential  CD77  (globotria- 
osyl ceramide)-binding  site (45). Together,  these structural 
features suggest that a ligand for CD19  may exist.  In addi- 
tion,  CD19  is a  major component  of the  signal  transduc- 
tion  complex associated with  the  CD21  (IFN-0t receptor) 
molecule  (for reviews see references 46,  47).  In our hands, 
however, IFN-0t or anti-CD21  mAbs displayed only a lim- 
ited effect on CPM  induction,  suggesting that,  if it plays a 
role  in  human  GC  formation,  CD19  might  act  indepen- 
dently of CD21. 
Unlike  CD19  +  BCR  stimulation,  CD40  +  BCR  co- 
triggering drives resting B lymphocytes to exhibit seven GC 
phenotypic  features,  including  the  lack  of surface  CD24 
and  the  presence  of markers  like  CD80,  CD86,  CD7I, 
CD95,  and  CD38.  The  latter  could  possibly  result  from 
anti-BCR-induced  endogenous  IFN-cl  production  (48). 
However,  CD40  +  BCR  stimulation  could  not  generate 
CD10 +  or CD44-  cells,  thus suggesting  that other stimuli 
are  required  for  modulating  these  markers.  It  should  be 
noted  that,  in  vivo,  CD40-CD40  ligand  contact  is  short 
lasting  and  tightly  regulated.  Indeed,  within  hours  after 
contact, CI)40 is released from APC--presumably through 
proteolitic cleavage (49)--whereas CD40 ligand is internal- 
ized in T  cells (50). Thus, two step culture experiments us- 
ing CD40  +  BCR-prestimulated  B  cells are in progress to 
identify  the  factors  responsible  for  the  generation  of 
CD44-  or CD10 +  B  cells.  Interestingly,  CD40  +  BCR- 
activated  B  cells  undergo  spontaneous  cell  death  in  me- 
dium  that  is  reminiscent  of the  apoptosis  of GC  B  cells. 
This in vitro-induced  cell death is likely to be the result of 
continuous  triggering of BCR, and is observed on cells ex- 
hibiting  high  levels of Bcl-2  protein.  The  mechanisms  re- 
sponsible  for  this  cell  death  induction  are  unknown  and 
could be dependent  upon the expression of other survival/ 
death  genes.  Because  lymphocytes undergoing  in vivo so- 
matic  hypermutation  are  highly  susceptible  to  apoptotic 
cell  death  (21),  we  are  presently  investigating  whether 
CD40  +  BCR~stimulated  naive  B  cells  undergo  somatic 
mutation  in  culture.  In conclusion,  our  results  imply that 
the acquisition ofa GC phenotype requires efficient cotrig- 
gering  of BCR  and  CD40.  They also  show  that  IFNs or 
CD19  triggering  could contribute  to the induction  of GC 
markers in humans.  Finally,  consistent  with  earlier  reports 
on  freshly  isolated  GC  cells,  in  vitro  acquisition  of a  GC 
phenotype  renders  resting  B  lymphocytes  highly  suscepti- 
ble to spontaneous cell death. 
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